Transforming the Understanding and Treatment of Neurodegeneration
ImmunoBrain Checkpoint is a clinical-stage biopharmaceutical company committed to developing innovative immunotherapies for neurological disorders.
Prof. Michal Schwartz suggests the concept of “Protective Autoimmunity”, and that peripheral immune cells play a critical role in shaping brain function.
ImmunoBrain Checkpoint is founded
ImmunoBrain Checkpoint, Inc. incorporates and enters a Research and License Agreement with Yeda, the commercialization company of the Weizmann Institute of Science to develop and commercialize the technology that emerges out of the Schwartz lab.
Immune checkpoint blockade
First evidence that immune checkpoint therapeutic approach can be utilized for treating Alzheimer's disease (Baruch et al., 2016, Nature Medicine).
Lead selection and optimization
ImmunoBrain Checkpoint licenses the rights to develop and commercialize a novel, fully human anti-PD-L1 antibody from Kymab (now a Sanofi company).
Regulatory approvals received to initiate clinical study in Europe.
IBC-01-01 clinical study
ImmunoBrain Checkpoint initiates IBC-01-01 Trial, a randomized, double-blind, placebo-controlled, first-in-human Phase Ib clinical trial in persons with early Alzheimer’s disease.